Progrip™ Self-Gripping Polypropylene Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists in procedures involving inguinal and ventral hernia repair by open approach.

Device Description

Progrip™ self-gripping polypropylene mesh is a sterile non-pyrogenic device made of a non-absorbable knitted monofilament polypropylene textile with resorbable polylactic acid (PLA) monofilament grips on one side.

Progrip™ self-gripping polypropylene mesh is available in different shapes and sizes.

The non-absorbable textile is designed to ensure long term reinforcement of soft tissues.

The monofilament polylactic acid grips facilitate placing and positioning the mesh, and they contribute to fixation of the mesh to the surrounding tissue for at least eight (8) weeks. The polylactic acid grips are bioresorbable. Over the time, they resorb in vivo by hydrolysis and are metabolized by the body into CO2 and H2O. Preclinical studies showed that the polylactic acid material is essentially resorbed in 36 to 50 months post-implantation. However, the resorption period depends on numerous factors including patient-related factors.

Progrip™ self-gripping polypropylene mesh is a single use device, presented in a double sterile barrier packaging (two Tyvek® pouches). The packed device is terminally sterilized by Ethylene Oxide (EtO) and placed into a commercial envelope with the Instructions for Use (IFU) and Patient Implant Card (PIC). All the devices are packaged unitary in a commercial envelope (single pack configuration: 1 unit per commercial envelope).

AI/ML Overview

The provided text is a 510(k) summary for the Progrip™ Self-Gripping Polypropylene Mesh (K232373). It details the device's characteristics and its substantial equivalence to predicate devices, but it does not contain information about acceptance criteria or a study proving the device meets acceptance criteria.

The document discusses various performance tests conducted (sterilization, shelf-life, shipping, biocompatibility, in vitro bench tests) to demonstrate substantial equivalence to the predicate device. However, these are presented as evaluations against established standards and guidance documents, rather than against specific, numerical acceptance criteria for a new clinical study.

Furthermore, the document explicitly states: "This premarket submission does not rely on the assessment of clinical performance data to demonstrate substantial equivalence." This indicates that no clinical study was performed for this 510(k) submission.

Therefore, I cannot provide the requested information regarding acceptance criteria, study details, sample sizes, expert qualifications, or ground truth establishment because this type of data is not present in the provided text. The submission relies on non-clinical performance and a comparison to predicate devices to establish substantial equivalence.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

January 18, 2024

Sofradim Production % Nancy Sauer Regulatory Affairs Senior Director Covidien Ilc 200 Medtronic Drive Lafayette, Colorado 80026

Re: K232373

Trade/Device Name: Progrip™ Self-Gripping Polypropylene Mesh Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh Regulatory Class: Class II Product Code: FTL Dated: December 18, 2023 Received: December 18, 2023

Dear Nancy Sauer:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Tek N.Lamichhane -S	Digitally signed by TekN. Lamichhane -SDate: 2024.01.1815:36:39 -05'00'
Tek Lamichhane, Ph.D.
Assistant Director
DHT4B: Division of Infection Controland Plastic and Reconstructive Surgery Devices
OHT4: Office of Surgicaland Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

{2}------------------------------------------------

Enclosure

{3}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) K232373

Device Name

ProGrip™ Self-Gripping Polypropylene Mesh

Indications for Use (Describe)

ProGrip™ Self-Gripping Polypropylene Mesh is intended to be used for the reinforcement of abdominal wall soft tissues where weakness exists in procedures involving inguinal and ventral hernia repair by open approach.

Type of Use (Select one or both, as applicable)
☒Prescription Use (Part 21 CFR 801 Subpart D) ☐Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) Summary

Date Prepared:	Jan 17, 2024
Submitter:	Sofradim Production (subsidiary of Covidien Ilc116, avenue du Formans01600 Trevoux, FranceTelephone: +33 (0)4 74 08 90 00Fax: +33 (0) 4 74 08 90 02
Contact:	Nancy SauerRegulatory Affairs Senior Director200 Medtronic Dr.Lafayette, CO 80026Phone: 720-361-5290Email: nancy.k.sauer@medtronic.com
Name of device:
Trade/Proprietary name:	Progrip™ self-gripping polypropylene mesh
Common name:	Surgical Mesh
Classification name:	Mesh, Surgical, PolymericProduct code: FTLRegulation number: 21 CFR 878.3300
Predicate Device:
Trade/Proprietary name:	Progrip™ self-gripping polyester mesh
Common name:	Surgical Mesh
Classification name:	Mesh, Surgical, PolymericProduct code: FTLRegulation number: 21 CFR 878.3300
510(k) Number:	K220586
Manufacturer:	Sofradim Production (subsidiary of Covidien Ilc)116, avenue du Formans01600 Trevoux, France
Reference Device:
Trade/Proprietary name:	PROLENE® Soft Polypropylene Mesh
Common name:	Surgical Mesh
Classification name:	Mesh, Surgical, PolymericProduct code: FTLRegulation number: 21 CFR 878.3300
510(k) Number:	K172089
Trade/Proprietary name:	Progrip™ self-gripping polypropylene mesh
Common name:	Surgical Mesh
Classification name:	Mesh, Surgical, PolymericProduct code: FTLRegulation number: 21 CFR 878.3300
510(k) Number:	K220540
Manufacturer:	Sofradim Production (subsidiary of Covidien Ilc)116, avenue du Formans01600 Trevoux France

{5}------------------------------------------------

Manufacturer: Ethicon, Inc. a Johnson & Johnson company P.O. Box 151 Route 22 West Somerville, NJ 08876-0151

Reference Device:

Progrip™ self-gripping polypropylene mesh is designed to allow Device Description: extraperitoneal mesh placement for the repair of inquinal and ventral hernias by open approach.

Progrip™ self-gripping polypropylene mesh is available in different shapes and sizes.

The non-absorbable textile is designed to ensure long term reinforcement of soft tissues.

Intended Use: Reinforcement of soft tissue where weakness exists.

{6}------------------------------------------------

Indications for use:

Progrip™ self-gripping polypropylene mesh is intended for use in reinforcement of abdominal wall soft tissue where weakness exists, in procedures involving inguinal and ventral hernia repair by open approach.

Summary comparing the technological characteristics of the subject and predicate device:

The subject device is substantially equivalent to Progrip™ self-gripping polyester mesh (K220586), which is the primary predicate device.

	Progrip™ self-grippingpolypropylene meshK232373(subject device)	Progrip™ self-gripping polyestermesh (K220586)(predicate device)	Comparison
Intended Use	Reinforcement of softtissue where aweakness exists	Reinforcement of softtissue whereweakness exists.	Same
Classification	FTL, per 21 CFR878.3300	FTL, per 21 CFR878.3300	Same
Indications foruse	Inguinal and ventralhernias repair	Inguinal and incisionalhernias repair	Different
Method ofInsertion	Open	Open andLaparoscopic(conventional androbotically assistedapproach)	Equivalent
Location ofplacement	Extraperitoneal	Extraperitoneal	Same
Defect Closure	Recommended	Recommended	Same
Materials	Surgical mesh, textilebased, knitted,monofilament,synthetic made ofpolypropylene andpolylactic acid yarns	Surgical mesh, textilebased, knitted,monofilament,synthetic made ofpolyester andpolylactic acid yarnsonly for elliptic(precut) codes:polyester yarn markerdyed with D&C blueno. 6.	Different
Shape	Rectangular andsquare	Rectangular andsquareElliptic	Equivalent
Sizes	Rectangular andsquare:15x15cm20x15cm30x20 cm30x30cm40x30cmThe mesh may berecut as needed	- Rectangular:15x9 cm15x15 cm20x15 cm30x15 cm- Elliptic, slit withoverlapping flap leftside/right side: 12x8cmThe mesh may berecut as needed	Different

Texture	Two-dimensionalmonofilament textilewith monofilamentabsorbable grips onone side of the mesh	Two-dimensionalmonofilament textilewith monofilamentabsorbable grips onone side of the mesh	Same
Pore size	$1.6\pm0,1$ mm and$0.6\pm0,0$ mm	$1.6\pm0,1$ mm and$0.6\pm0,1$ mm	Same
Fixationinstructions	The technique used to fixate the mesh (sutureand/or tacks) is left up to the surgeon.Compatibility with other fixation devices maynot have been established. Using means offixation other than those for which compatibilityis established may lead to mesh damage. Iftacks are used to fixate the mesh, the use ofCovidienTM fixation devices is recommended. Itis suggested to fixate the mesh at a distance ofapproximately 1 cm from the edge of the mesh.The textile self-gripping feature makes itpossible to position the mesh without fixation,depending on the size of the defect, the herniaposition and the quality of the anatomicalstructures.	The technique used to fixate the mesh (sutureand/or tacks) is left up to the surgeon.Compatibility with other fixation devices maynot have been established. Using means offixation other than those for which compatibilityis established may lead to mesh damage. Iftacks are used to fixate the mesh, the use ofCovidienTM fixation devices is recommended. Itis suggested to fixate the mesh at a distance ofapproximately 1 cm from the edge of the mesh.The textile self-gripping feature makes itpossible to position the mesh without fixation,depending on the size of the defect, the herniaposition and the quality of the anatomicalstructures.	Same
Sterilization	Ethylene Oxide	Ethylene Oxide	Same
Packaging	Sealed Tyvek®//polyester/polyethylenepouch (double sterilebarrier system)	Sealed Tyvek®//polyester/polyethylenepouch (double sterilebarrier system)	Same

{7}------------------------------------------------

The subject device and predicate device have the same intended use and nearly identical indications for use, differing only in the addition of primary ventral hernia repair for the subject device. Differences in the technological characteristics between the subject and predicate devices do not raise new questions of safety or effectiveness. Performance testing demonstrated substantial equivalence for biocompatibility, has mechanical properties such as strength, human factors evaluation, sterilization, packaging, transport and shelf life.

This 510(k) also references the PROLENE® Soft Polypropylene Mesh (K172089) and the Progrip™ self-gripping polypropylene mesh (K220540). PROLENE® Soft Polypropylene Mesh (K172089) was selected because this legally marketed mesh includes large sizes (up to 50x50cm). Progrip™ self-gripping polypropylene mesh (K220540) was selected because this legally marketed mesh presents the same base materials as the subject device.

Performance data: The following performance data is provided in support of substantial equivalence demonstration:

. Sterilization: the sterilization process has been validated in accordance with ISO 11135 (2014) and AAMI TIR28 (2016) standards.

{8}------------------------------------------------

Shelf-life: the 5-year shelf life has been demonstrated for the subject ● device.
Shipping test: shipping test was performed in accordance with the . ASTM D4169 (2022) standard.
Biocompatibility: biocompatibility evaluation was performed for the ● subject Progrip™ self-gripping polypropylene mesh in accordance with the FDA quidance "Use of International Standard ISO 10993-1. "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" issued September 4, 2020, and international standard ISO 10993-1 (2018). The subject device meets the criteria for biocompatibility set forth in the FDA guidance and ISO standard.
Performance testing In vitro (bench) tests has been performed to . compare the subject and predicate in accordance with the FDA Guidance "Guidance for the Preparation of a Premarket Notification Application of a Surgical Mesh" issued March 2, 1999. Results demonstrate that physical and mechanical performance of the subject are substantially equivalent to the predicate.
Human factors evaluation was conducted. A comparison of the critical tasks of the subject device and the predicate device was performed. The critical tasks are the same and there are no critical tasks introduced and no existing critical tasks have been impacted. Therefore, human factors data are not needed to demonstrate substantial equivalence.

This premarket submission does not rely on the assessment of clinical performance data to demonstrate substantial equivalence.

Conclusion:

Comparison of the subject and predicate devices and labeling as well as the results of performance testing demonstrate that the subject Progrip™ self-gripping polypropylene mesh is substantially equivalent to the predicate device Progrip™ self-aripping polvester mesh (K220586).

Regulation Number and Section

§ 878.3300 Surgical mesh.

(a)
Identification. Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.(b)
Classification. Class II.